RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer-Reference-Cited by-同舟云学术

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Published:2016-07-04 Issue:8 Volume:108 Page:djw111
ISSN:0027-8874
Container-title:Journal of the National Cancer Institute
language:en
Short-container-title:JNCI J Natl Cancer Inst

Author:

Toomey Sinead,Eustace Alex J.,Pritzker Laura B.,Pritzker Ken P. H.,Fay Joanna,O’Grady Anthony,Cummins Robert,Grogan Liam,Kennedy John,O’Connor Darran,Young Leonie,Kay Elaine W.,O’Donovan Norma,Gallagher William M.,Kalachand Roshni,Crown John,Hennessy Bryan T.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/108/8/djw111/17987249/djw111.pdf

Reference5 articles.

1. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy

2. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy

3. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”

4. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

5. Crown J Coate L Keane M , . Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05. Cancer Res. 2013;73(24 Suppl): abstract nr P4-12-25.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study);BMC Cancer;2024-01-17

2. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer;JNCI Cancer Spectrum;2023-12-19

3. Association of extensive RNA disruption with natural killer cell-mediated death of K562 chronic myelogenous leukemia cells;2023-06-05

4. RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells;Scientific Reports;2023-01-31

5. Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach;Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer;2023-01